Skip to content
HowShorted

HERON THERAPEUTICS, INC. short interest in 2023

In 2023, HERON THERAPEUTICS, INC.'s disclosed short interest ran from 22.77% of shares outstanding on 13 Jan 2023 to 13.47% on 29 Dec 2023, a change of -9.30 percentage points. The year's high was 22.77% on 13 Jan 2023 and its low 11.72% on 15 Nov 2023, averaging 17.93% across 24 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 21.11 days on 14 Jul 2023. Full history: HERON THERAPEUTICS, INC..

Cite this page
Plain
Wikipedia
BibTeX

By year: 2018 · 2019 · 2020 · 2021 · 2022 · 2023 · 2024 · 2025 · 2026

Aggregate net short position time series for HERON THERAPEUTICS, INC. in 2023

2023 in figures

Start of year
22.77% (13 Jan 2023)
End of year
13.47% (29 Dec 2023)
Change
-9.30 pp
High
22.77% (13 Jan 2023)
Low
11.72% (15 Nov 2023)
Average
17.93%
Highest days to cover
21.11 (14 Jul 2023)
SEC filings marked
9

Every report in 2023

HERON THERAPEUTICS, INC. short interest in 2023
SettlementShort interestDays to coverFilings since previous
13 Jan 202322.77%16.99results (8-K)
31 Jan 202322.53%15.03
15 Feb 202321.98%15.31
28 Feb 202319.57%14.11
15 Mar 202319.12%14.58
31 Mar 202319.41%10.22results (8-K), 10-K filed
14 Apr 202319.44%5.63
28 Apr 202318.70%13.17
15 May 202318.16%7.0110-Q filed, results (8-K)
31 May 202319.61%8.97
15 Jun 202319.20%10.94
30 Jun 202318.81%11.35
14 Jul 202318.63%21.11
31 Jul 202317.27%9.16
15 Aug 202319.72%10.6410-Q filed, results (8-K)
31 Aug 202317.99%17.36
15 Sep 202318.29%17.79
29 Sep 202318.71%16.54
13 Oct 202313.75%5.51
31 Oct 202313.08%9.75
15 Nov 202311.72%4.2710-Q filed, results (8-K)
30 Nov 202314.38%4.75
15 Dec 202314.00%7.53
29 Dec 202313.47%10.02

See also: HERON THERAPEUTICS, INC.'s full history · most shorted US stocks of 2023 · today's US league.

About this data

US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.